Ischemic Heart Disease Clinical Trial
— mStress-IHDOfficial title:
A mHealth Intervention to Reduce Perceived Stress in Patients With Ischemic Heart Disease
Stress is highly prevalent in patients with ischemic heart disease (IHD) and is associated with lower health-related quality of life and worsened cardiovascular outcome. The importance of stress management is now recognized in recent cardiovascular guidelines. However, effective stress management intervention are not implemented in clinical routine yet. The development of easily disseminated eHealth interventions, particularly mHealth, may offer a cost-effective and scalable solution to this problem. The aim of the proposed trial is to assess the efficiency and cost-effectiveness of the mHealth intervention 'mindfulHeart' in terms of reducing stress in patients with IHD.
Status | Not yet recruiting |
Enrollment | 128 |
Est. completion date | May 1, 2025 |
Est. primary completion date | May 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - confirmed diagnosis of IHD - elevated perceived stress for at least 4 weeks - own an Internet-enabled smartphone and know how to use it - have provided written informed consent Exclusion Criteria: - Participants who have severe cognitive impairment and/or communication difficulties that may affect their ability to participate in the study - psychiatric or medical conditions that require alternative treatment - no private internet access |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Essen | Universität Duisburg-Essen |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Treatment satisfaction | the adapted German version of the Client Satisfaction Questionnaire for Internet-based interventions (CSQ-I) is an 8-item assessment instrument that evaluates participants' overall satisfaction with the intervention. Responses are measured on a 4-point Likert scale. | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Other | Usability | The System Usability Scale is used to assess the usability of the intervention, which is a 10-item questionnaire rated on a 5-point Likert scale. To determine the perceived usefulness of our healthcare smartphone app, we will also use a healthcare smartphone app evaluation survey. Responses are measured on a 4-point Likert scale. | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Other | Predictors of usage behavior | assessing the predictors of actual usage behavior is crucial as interventions can only benefit patients who use them. Therefore, it is important to evaluate the predictors of uptake for the intervention. In order to do so, the Unified Theory of Acceptance and Use of Technology and it modified questionnaire will be applied [52]. | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Other | Cost-effectiveness | the objective of conducting an economic evaluation is to assess the cost-effectiveness of the intervention from the viewpoint of payers. This evaluation will involve a cost-effectiveness analysis and will be calculated based on the EQ-5D-5L questionnaire. | after 15 months | |
Other | Cost-utility | To determine the cost-utility, quality-adjusted life years will be calculated based on the EQ-5D-5L questionnaire. The resource utilization will be evaluated by means of a questionnaire and will be measured in monetary units using the established standards of health economics. Furthermore, the costs per reduced unit of stress are assessed and compared between the intervention group and control group. | after 15 months | |
Primary | combined global stress measure | The outcome is based on a published RCT in Circulation by Blumenthal et al. [34]. A global stress measure (mean rank), was the primary outcome combining the following components at baseline and following treatment: Beck Depression Inventory II, Spielberger Anxiety Inventory-State, General Health Questionnaire, PROMIS Anger Questionnaire, and Perceived Stress Scale. A range from 1 to 147 was present with higher scores suggestive of better function. The change in each individual scaled score is presented in primary outcome 2. (see also NCT00981253) | 3 months, after intervention | |
Secondary | Health-related quality of life | we will apply two instrument to measure health-related quality of life. Namely the Short Form-36 health questionnaire and the European Quality of Life 5 Dimensions 5 Level survey (EQ-5D-5L) [36,37]. The SF-36 is an eight-dimensional scale consisting of 36 items. It assesses health-related quality of life based on physical, social, and psychological functioning, role behavior due to physical and psychological functional impairment, physical pain, general health perception, and vitality. The EQ-5D-5L consists of five health-related dimensions that can be assessed at five levels. In addition, the questionnaire contains a visual analog scale for assessing general health | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | Disease-specific effect of angina on patients' physical function and quality of life | We will also include the Seattle Angina Questionnaire (SAQ). The 7-item version of the SAQ is a shortened version of the original 19-item SAQ and has been shown to be highly valid, reliable, and sensitive to clinical change. These ranges of SAQ scores are strongly and independently correlated with the risk of subsequent death, the risk of myocardial infarction, and health care costs | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | Changes in functional capacity | changes in functional capacity will be recorded using the established 6-minute walk test | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | Blood pressure | To evaluate the effect of the intervention on blood pressure , this parameters will be assessed with the average of three consecutive measurements at rest. The standard measurement approach was always performed in the same quiet room at a consistent controlled temperature and after a resting period of at least 20 minutes. The same examination sequence was maintained for all study subjects. To obtain reliable measurements, the patients were asked not to speak and to lie quietly during the entire measurement. | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | Heart rate | To evaluate the effect of the intervention on heart rate , this parameters will be assessed with the average of three consecutive measurements at rest. The standard measurement approach was always performed in the same quiet room at a consistent controlled temperature and after a resting period of at least 20 minutes. The same examination sequence was maintained for all study subjects. To obtain reliable measurements, the patients were asked not to speak and to lie quietly during the entire measurement. | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | Self-efficacy | To evaluate self-efficacy, we will utilize the Generalized Self-Efficacy Scale (GSES) in its German version [41]. The GSES is a self-administered questionnaire that measures an individual's optimistic self-beliefs and self-efficacy in dealing with challenging demands and stressful events in life. Each of the 10 items is rated on a 4-point Likert scale. | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | combined global stress measure | The outcome is based on a published RCT in Circulation by Blumenthal et al. [34]. A global stress measure (mean rank), was the primary outcome combining the following components at baseline and following treatment: Beck Depression Inventory II, Spielberger Anxiety Inventory-State, General Health Questionnaire, PROMIS Anger Questionnaire, and Perceived Stress Scale. A range from 1 to 147 was present with higher scores suggestive of better function. The change in each individual scaled score is presented in primary outcome 2. (see also NCT00981253) | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | Depression symptoms (BDI-II) | The BDI-II is a self-report questionnaire comprising 21 items that assess depression severity. Its reliability and validity have been established through various studies among diverse populations and cultural backgrounds. Higher scores indicates increased depression symptoms | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | Anxiety symptoms (STAI) | The STAI is the most authoritative tool for assessing anxiety in adults, precisely distinguishing between transient "state anxiety" and persistent "trait anxiety". The STAI measures anxiety with 20 items and has a range of 20 to 80. A higher score indicates more pronounced anxiety | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | PROMIS-Anger Scale | The PROMIS Anger scale comprises eight items that evaluate various aspects of anger. Scores on the scale range from 8 to 40, with higher scores indicating greater levels of anger | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | GHQ | The GHQ assesses general distress and consists of 12 items. Respondents' scores range from 0 to 36, where higher scores correspond to increased distress | Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months | |
Secondary | Perceived Stress Scale | The Perceived Stress Scale-10 item version is a short tool for the assessment of how individuals perceive stress in their lives. The values range from 0 to 40. Higher values indicate higher perceived stress [46].
(l) In-treatment assessments: at the start of each intervention module (weekly), the following assessment instruments will be applied: Distress Thermometer (DT), Patient Health Questionnaire-4 (PHQ-4) and self-generated measures to assess coping skills and self-efficacy |
Baseline, after 3 months, after 4 months, after 6 months, after 9 months, after 15 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Active, not recruiting |
NCT04562805 -
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
|
N/A | |
Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Not yet recruiting |
NCT04153383 -
Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
|
||
Recruiting |
NCT02982434 -
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
|
Phase 2 | |
Recruiting |
NCT02729064 -
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
|
Phase 1 | |
Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
Completed |
NCT02759406 -
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT01699802 -
Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)
|
N/A | |
Completed |
NCT01604213 -
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01334268 -
RESOLUTE China RCT
|
N/A | |
Completed |
NCT01724567 -
Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training
|
N/A | |
Completed |
NCT02159235 -
Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
|
N/A |